LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.

Lapietra, Gianfranco / Fazio, Francesca / Petrucci, Maria Teresa

2022 Volume 12, Issue 8

Abstract: Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate network of interactions between bone marrow-resident clonal plasma cells and the microenvironment. Over the last years, dramatic improvement in the understanding of ... ...

Abstract	Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate network of interactions between bone marrow-resident clonal plasma cells and the microenvironment. Over the last years, dramatic improvement in the understanding of these pathways led to the introduction of novel drugs with immune-mediated mechanisms of action. Some of these compounds, such as the anti-cd38 daratumumab and isatuximab, the anti-slamf-7 elotuzumab, and the antibody-drug conjugate belantamab-mafodotin, have been tested in large clinical trials and have now fully entered the real-life management. The bispecific T-cell engagers are under investigation with promising results, and other satisfactory data is expected from the application of nanotechnologies. The perfect timing to introduce these drugs in the sequence of treatment and their adverse events represent new challenges to be addressed, and further experience is required to improve their use.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Humans ; Immunotherapy/methods ; Multiple Myeloma/drug therapy ; T-Lymphocytes ; Tumor Microenvironment
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents, Immunological
Language	English
Publishing date	2022-08-19
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2701262-1
ISSN	2218-273X ; 2218-273X
ISSN (online)	2218-273X
ISSN	2218-273X
DOI	10.3390/biom12081146
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Immune thrombocytopenia management during COVID-19 pandemic: An Italian monocentric experience.

Lapietra, Gianfranco / Ferretti, Antonietta / Baldacci, Erminia / Chistolini, Antonio / Santoro, Cristina

EJHaem

2022 Volume 3, Issue 2, Page(s) 453–456

Abstract: Over the last 2 years, different cases of immune thrombocytopenia (ITP) in patients affected by SARS-CoV2 have been reported. The management of SARS-CoV2 in subjects with simultaneous or previous ITP can be challenging because of the great involvement of ...

Abstract	Over the last 2 years, different cases of immune thrombocytopenia (ITP) in patients affected by SARS-CoV2 have been reported. The management of SARS-CoV2 in subjects with simultaneous or previous ITP can be challenging because of the great involvement of the haemostatic system in this viral infection. In this report, we describe the management and outcome of patients with newly diagnosed (ND), chronic and previous ITP, infected by COVID-19, referred to the Haematology Institute of University Hospital Policlinico Umberto I in Rome. Steroids + immunoglobulins for ND or relapsed ITP and continuation of home therapy for chronic ITP are advised, although further knowledge is required.
Language	English
Publishing date	2022-03-09
Publishing country	United States
Document type	Journal Article
ISSN	2688-6146
ISSN (online)	2688-6146
DOI	10.1002/jha2.406
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.

Lapietra, Gianfranco / Limongi, Maria Zaira / Buffolino, Sonia / Nanni, Mauro / Ballarò, Daniele / Martelli, Maurizio / Mancini, Marco

Leukemia research

2023 Volume 126, Page(s) 107035

MeSH term(s)	Humans ; Polycythemia Vera/drug therapy ; Imatinib Mesylate/therapeutic use ; Janus Kinase 2/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications ; Leukemia, Myeloid
Chemical Substances	Imatinib Mesylate (8A1O1M485B) ; Janus Kinase 2 (EC 2.7.10.2) ; JAK2 protein, human (EC 2.7.10.2)
Language	English
Publishing date	2023-02-08
Publishing country	England
Document type	Letter
ZDB-ID	752396-8
ISSN	1873-5835 ; 0145-2126
ISSN (online)	1873-5835
ISSN	0145-2126
DOI	10.1016/j.leukres.2023.107035
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1321: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?

Lapietra, Gianfranco / Serrao, Alessandra / Fazio, Francesca / Petrucci, Maria Teresa / Chistolini, Antonio

Journal of thrombosis and thrombolysis

2021 Volume 52, Issue 2, Page(s) 584–589

Abstract: Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs. In multiple myeloma patients, the risk is increased by use of ... ...

Abstract	Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs. In multiple myeloma patients, the risk is increased by use of immunomodulants, especially when associated to multidrug therapy, during the induction phase. Prevention of venous thromboembolism in myeloma patients is highly recommended but specific guidelines are still lacking. The most common approach is to stratify the thrombotic risk according to individual, myeloma-related and therapy-related risk factors and to use aspirin for all patients, except those with two or more thrombotic risk factors who should be treated with traditional oral or parenteral anticoagulant. A more controversial approach indicates for prophylaxis either anticoagulant or aspirin, regardless of risk stratification. Recent trials investigate prophylaxis in myeloma patients with direct oral anticoagulants, based on studies showing efficacy and safety of this new class of drugs in the treatment and prophylaxis of thrombosis in patients with any malignancy. The results of these trials are encouraging but they need to be confirmed by larger studies. An international consensus about best prophylaxis to prevent venous thromboembolism in patients with multiple myeloma on treatment is still missing. Therefore, thrombosis in multiple myeloma remains an ongoing issue.
MeSH term(s)	Anticoagulants/therapeutic use ; Aspirin/therapeutic use ; Drug Therapy, Combination ; Humans ; Leprostatic Agents/therapeutic use ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Pharmaceutical Preparations ; Thrombosis/drug therapy ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/etiology ; Venous Thromboembolism/prevention & control
Chemical Substances	Anticoagulants ; Leprostatic Agents ; Pharmaceutical Preparations ; Aspirin (R16CO5Y76E)
Language	English
Publishing date	2021-01-08
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1230645-9
ISSN	1573-742X ; 0929-5305
ISSN (online)	1573-742X
ISSN	0929-5305
DOI	10.1007/s11239-020-02354-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation.

Cenfra, Natalia / Lapietra, Gianfranco / Perrone, Salvatore / Voso, Maria Teresa / Divona, Mariadomenica / Mecarocci, Sergio / La Barbera, Elettra Ortu / Cimino, Giuseppe

Chemotherapy

2022 Volume 67, Issue 1, Page(s) 24–28

Abstract: Acute myeloid leukemia (AML) is the most common leukemia in adults. In spite of the most recent discoveries about the molecular landscape of this disease, the treatment of elderly and unfit young patients continues to be a great challenge. The ... ...

Abstract	Acute myeloid leukemia (AML) is the most common leukemia in adults. In spite of the most recent discoveries about the molecular landscape of this disease, the treatment of elderly and unfit young patients continues to be a great challenge. The hypomethylating agents (HMA) still represent an effective therapeutic option for these categories, especially for the low-risk subgroups. We report the case of a young patient with NPM1mut-AML who underwent a first cycle of intensive induction treatment, achieving a complete remission, but suffered from a serious life-threatening neurologic toxicity. Due to the ineligibility to further lines of intensive chemotherapy, we decided to consolidate the response with azacitidine, administered according to the regular schedule. The minimal residual disease (MRD), monitored through the NPM1 mutation at diagnosis, progressively decreased and became undetectable after 36 cycles of hypomethylating therapy. After 1 year from discontinuation of azacitidine, MRD remains undetectable. Therefore, HMA might still represent a feasible and effective option for patients with low-risk AML, especially when the standard chemotherapy is not indicated, or as maintenance therapy in nontransplantable patients.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Azacitidine/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Neoplasm, Residual/drug therapy ; Remission Induction
Chemical Substances	Azacitidine (M801H13NRU)
Language	English
Publishing date	2022-01-12
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	6708-8
ISSN	1421-9794 ; 0009-3157
ISSN (online)	1421-9794
ISSN	0009-3157
DOI	10.1159/000520205
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.174: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Monoclonal antibodies in multiple myeloma.

Vozella, Federico / Fazio, Francesca / Lapietra, Gianfranco / Petrucci, Maria T / Martinelli, Giovanni / Cerchione, Claudio

Panminerva medica

2020 Volume 63, Issue 1, Page(s) 21–27

Abstract: Treatment of multiple myeloma (MM) patients has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivative (IMiDs). In the last years, one further therapeutic option for ... ...

Abstract	Treatment of multiple myeloma (MM) patients has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivative (IMiDs). In the last years, one further therapeutic option for MM patients is represented by monoclonal antibodies (MoAbs), that seem to change the paradigm of MM treatment, particularly for heavily pretreated or double refractory to a PI and IMiDs patients. Antibodies have an immune-based mechanism, induce durable responses with limited toxicity and combine well with existing therapies. The therapeutic effects are prevalently obtained by means of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and concurrently by the induction of signals on cell effectors. Immunotherapeutic strategies offer a new and exciting approach to target key molecular pathways that continue to be implicated in the survival of malignant plasma cells. These targets include cell surface proteins (CD38, CD138 [SDC1], B cell maturation antigen [BCMA, TNFRSF17]), cytokines that play a role in plasma cell survival and proliferation (interleukin 6 [IL6] and B cell activating factor), signal regulators of bone metabolism (RANKL [TNFSF11], DKK1) and regulators of the immune system (PD-1[PDCD1], PD-L1[CD274]). This article focuses on new MoAbs and related innovative immunotherapeutic modalities currently under investigation in the treatment landscape of MM.
MeSH term(s)	Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/mortality ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents, Immunological
Language	English
Publishing date	2020-09-21
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	123572-2
ISSN	1827-1898 ; 0031-0808
ISSN (online)	1827-1898
ISSN	0031-0808
DOI	10.23736/S0031-0808.20.04149-X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 179: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience.

Fazio, Francesca / Lapietra, Gianfranco / Limongi, Maria Zaira / Intoppa, Stefania / Milani, Maria Laura / Piciocchi, Alfonso / Martelli, Maurizio / Guarini, Anna / Foà, Robin / De Propris, Maria Stefania / Petrucci, Maria Teresa

Mediterranean journal of hematology and infectious diseases

2023 Volume 15, Issue 1, Page(s) e2023047

Abstract: Multiple myeloma (MM) is a heterogeneous malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Multiparametric flow cytometry (MFC) plays a role in the work-up of the disease in view of the aberrant expression of ... ...

Abstract	Multiple myeloma (MM) is a heterogeneous malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Multiparametric flow cytometry (MFC) plays a role in the work-up of the disease in view of the aberrant expression of surface antigens. Our study aimed at describing the antigenic profile detected by MFC in a series of newly diagnosed MM patients to correlate the level of expression with other features of the disease. Between April 2018 and June 2022, 84 consecutive MM patients were studied at presentation. CD56 and CD117 were commonly detected, while CD45, CD28, CD20, CD19, CD13 and CD33 were less recurrent. CD20 expression was associated with the type of secretory MM (p=0.041) and with a higher disease burden (p=0.038). CD28 positivity correlated with a lower platelet count at baseline (p=0.005) and with a lower rate of complete response (p=0.038). Furthermore, CD28 positivity and a lower CD138 expression tended to associate with the high-risk chromosomal translocations t(14;16) and t(4;14). The results of this study indicate that in the diagnostic work-up of MM, MFC may help to identify different patient subsets and improve risk stratification. These observations need to be validated in larger series of patients with a longer follow-up.
Language	English
Publishing date	2023-09-01
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2674750-9
ISSN	2035-3006
ISSN	2035-3006
DOI	10.4084/MJHID.2023.047
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Direct oral anticoagulants in patients with hematologic malignancies.

Serrao, Alessandra / Fiori, Luciano / Santoro, Cristina / De Luca, Maria L / Ferretti, Antonietta / De Luca, Giulia / Ligia, Silvio / Lapietra, Gianfranco / Mohamed, Sara / Breccia, Massimo / Chistolini, Antonio

Hematological oncology

2020 Volume 38, Issue 4, Page(s) 589–596

Abstract: The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), which is considered the safest in this particular patients setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and ... ...

Abstract	The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), which is considered the safest in this particular patients setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and safety in patients with cancer, their use can be challenging in patients with hematologic malignancies due to the peculiarity of these neoplasms: high thrombotic risk, possible onset of thrombocytopenia and concomitant anticancer therapies. The aim of our study was to evaluate the efficacy and safety of DOACs for venous thromboembolism or atrial fibrillation in patients with hematologic malignancies and plasmatic DOACs level during anticancer therapy and at time of bleeding or thrombotic complications. We evaluated patients with hematologic malignancies treated with DOACs for venous thromboembolism or atrial fibrillation-therapy was maintained until the platelet count was ≥50 × 10
MeSH term(s)	Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Atrial Fibrillation/chemically induced ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/pathology ; Female ; Follow-Up Studies ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Hemorrhage/pathology ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Venous Thromboembolism/chemically induced ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/pathology
Chemical Substances	Anticoagulants
Language	English
Publishing date	2020-07-29
Publishing country	England
Document type	Journal Article
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.2770
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Polyostotic Fibrous Dysplasia Mimicking Bone Involvement in Hodgkin Lymphoma: A Pediatric Case and Literature Review.

Lapietra, Gianfranco / Moleti, Maria Luisa / Giona, Fiorina / Turchetti, Arianna / Celli, Mauro / Corsi, Alessandro / Zambrano, Anna / D'Avanzo, Miriam / Celli, Luca / Testi, Anna Maria

Acta haematologica

2020 Volume 144, Issue 2, Page(s) 212–217

Abstract: Bone involvement in Hodgkin lymphoma (HL) is rare. The differential diagnosis between HL bone localization and other malignant or benign skeletal diseases is challenging. We report the case of a girl affected by classic HL, initially staged IVA because ... ...

Abstract	Bone involvement in Hodgkin lymphoma (HL) is rare. The differential diagnosis between HL bone localization and other malignant or benign skeletal diseases is challenging. We report the case of a girl affected by classic HL, initially staged IVA because of supradiaphragmatic lymph nodes and skeletal involvement. After 6 ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) cycles, positron emission tomography (PET) showed a complete metabolic response of the nodal localizations and a persistent, high metabolic activity of bone lesions. Salvage treatment followed by autologous stem cell transplant was carried out. After the transplant, the bone lesions maintained a high metabolic activity at PET. A targeted bone biopsy led to the diagnosis of a fibrous dysplasia excluding the presence of HL. To our knowledge, the concomitant presence of HL and fibrous dysplasia has not been previously reported. An in-depth evaluation of disease response to frontline treatment with a biopsy of the PET-hypercaptant bone lesions could have avoided overtreatment in this patient.
MeSH term(s)	Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/administration & dosage ; Bone and Bones/diagnostic imaging ; Bone and Bones/pathology ; Dacarbazine/administration & dosage ; Diagnosis, Differential ; Doxorubicin/administration & dosage ; Female ; Fibrous Dysplasia, Polyostotic/complications ; Fibrous Dysplasia, Polyostotic/diagnosis ; Hodgkin Disease/complications ; Hodgkin Disease/diagnosis ; Hodgkin Disease/drug therapy ; Hodgkin Disease/therapy ; Humans ; Magnetic Resonance Imaging ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Stem Cell Transplantation ; Transplantation, Autologous ; Vinblastine/administration & dosage
Chemical Substances	Bleomycin (11056-06-7) ; Vinblastine (5V9KLZ54CY) ; Dacarbazine (7GR28W0FJI) ; Doxorubicin (80168379AG)
Language	English
Publishing date	2020-07-24
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	80008-9
ISSN	1421-9662 ; 0001-5792
ISSN (online)	1421-9662
ISSN	0001-5792
DOI	10.1159/000508261
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.145: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Book: Nuove possibilità di lotta contro il punteruolo del pioppo nel periodo autunno-invernale

Lapietra, Gianfranco

(Quaderni di ricerca / Centro di sperimentazione agricola e forestale [e] Istituto di sperimentazione per la pioppicoltura, Società agricola e forestale ; 16)

1987

Title translation	New possibilities of poplar weevil control by autumn-winter treatments.
Series title	Quaderni di ricerca / Centro di sperimentazione agricola e forestale [e] Istituto di sperimentazione per la pioppicoltura, Società agricola e forestale ; 16
Keywords	pesticides ; agrochemicals ; forestry ; plant pests ; plant health ; arthropod pests
Language	Italian
Size	9 p. :, ill. (some col.) ;, 27 cm.
Publisher	Società agricola e forestale
Publishing place	Roma
Document type	Book
Note	Cover title. ; Authored by Gianfranco Lapietra, Gianni Allegro. ; Summary in English.
Database	NAL-Catalogue (AGRICOLA)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

Your last searches

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED